Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?

Reza Mehrazin; Che Kai Tsao; John Sfakianos; Matthew D. Galsky

doi:10.1016/j.urolonc.2016.01.003

Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?

Reza Mehrazin, Che Kai Tsao, John Sfakianos, Matthew D. Galsky

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The role of adjuvant therapy for renal cell carcinoma (RCC) after surgical resection has been evaluated in numerous randomized and nonrandomized studies using systemic therapies with distinct mechanisms of action. However, adjuvant therapy has not demonstrated definitive benefit to date and guidelines currently do not support its use. Continued advancement in the understanding of the molecular pathogenesis in RCC is critical, which would lead to identification of new therapeutic targets, as well as novel prognostic and predictive biomarkers, in hopes of improving outcomes in this lethal disease. Herein we summarize the results of randomized studies of the adjuvant treatments of RCC, in hopes to direct future effort in the development of treatment of this disease.

Original language	English
Pages (from-to)	221-224
Number of pages	4
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	34
Issue number	5
DOIs	https://doi.org/10.1016/j.urolonc.2016.01.003
State	Published - 1 May 2016

Keywords

Adjuvant therapy
Clinical trials
Kidney cancer
Nephrectomy
Tyrosine kinase inhibitor

Access to Document

10.1016/j.urolonc.2016.01.003

Cite this

@article{0072e0432aff4d4bbde39e3ffcd64202,

title = "Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?",

abstract = "The role of adjuvant therapy for renal cell carcinoma (RCC) after surgical resection has been evaluated in numerous randomized and nonrandomized studies using systemic therapies with distinct mechanisms of action. However, adjuvant therapy has not demonstrated definitive benefit to date and guidelines currently do not support its use. Continued advancement in the understanding of the molecular pathogenesis in RCC is critical, which would lead to identification of new therapeutic targets, as well as novel prognostic and predictive biomarkers, in hopes of improving outcomes in this lethal disease. Herein we summarize the results of randomized studies of the adjuvant treatments of RCC, in hopes to direct future effort in the development of treatment of this disease.",

keywords = "Adjuvant therapy, Clinical trials, Kidney cancer, Nephrectomy, Tyrosine kinase inhibitor",

author = "Reza Mehrazin and Tsao, {Che Kai} and John Sfakianos and Galsky, {Matthew D.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = may,

day = "1",

doi = "10.1016/j.urolonc.2016.01.003",

language = "English",

volume = "34",

pages = "221--224",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Systemic adjuvant therapy for renal cell carcinoma

T2 - Any hope for future clinical trials?

AU - Mehrazin, Reza

AU - Tsao, Che Kai

AU - Sfakianos, John

AU - Galsky, Matthew D.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The role of adjuvant therapy for renal cell carcinoma (RCC) after surgical resection has been evaluated in numerous randomized and nonrandomized studies using systemic therapies with distinct mechanisms of action. However, adjuvant therapy has not demonstrated definitive benefit to date and guidelines currently do not support its use. Continued advancement in the understanding of the molecular pathogenesis in RCC is critical, which would lead to identification of new therapeutic targets, as well as novel prognostic and predictive biomarkers, in hopes of improving outcomes in this lethal disease. Herein we summarize the results of randomized studies of the adjuvant treatments of RCC, in hopes to direct future effort in the development of treatment of this disease.

AB - The role of adjuvant therapy for renal cell carcinoma (RCC) after surgical resection has been evaluated in numerous randomized and nonrandomized studies using systemic therapies with distinct mechanisms of action. However, adjuvant therapy has not demonstrated definitive benefit to date and guidelines currently do not support its use. Continued advancement in the understanding of the molecular pathogenesis in RCC is critical, which would lead to identification of new therapeutic targets, as well as novel prognostic and predictive biomarkers, in hopes of improving outcomes in this lethal disease. Herein we summarize the results of randomized studies of the adjuvant treatments of RCC, in hopes to direct future effort in the development of treatment of this disease.

KW - Adjuvant therapy

KW - Clinical trials

KW - Kidney cancer

KW - Nephrectomy

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84961219293&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2016.01.003

DO - 10.1016/j.urolonc.2016.01.003

M3 - Review article

C2 - 26997518

AN - SCOPUS:84961219293

SN - 1078-1439

VL - 34

SP - 221

EP - 224

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 5

ER -

Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?

Abstract

Keywords

Access to Document

Fingerprint

Cite this